1. Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy
   Miwa Adachi et al, 2015, Resistance to Immunotoxins in Cancer Therapy CrossRef
2. GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance
   Aki Inase et al, 2023, eJHaem CrossRef
3. Antibody-Based Treatment of Acute Myeloid Leukemia
   Phillip M. Garfin et al, 2016, Current Hematologic Malignancy Reports CrossRef
4. Generation of Antibody-Drug Conjugate Resistant Models
   Lucía Gandullo-Sánchez et al, 2021, Cancers CrossRef
5. Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy
   Hadi Nasiri et al, 2018, Journal of Cellular Physiology CrossRef
6. A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype
   John F. Marcelletti et al, 2023, Cancer Chemotherapy and Pharmacology CrossRef
7. Antibody-targeted drugs and drug resistance—Challenges and solutions
   LeeRon Shefet-Carasso et al, 2015, Drug Resistance Updates CrossRef
8. Drug Efflux Transporters and Multidrug Resistance in Acute Leukemia: Therapeutic Impact and Novel Approaches to Mediation
   Cindy Q. Xia et al, 2012, Molecular Pharmacology CrossRef
9. Design, synthesis and biological profile of new inhibitors of multidrug resistance associated proteins carrying a polycyclic scaffold
   Alessandra Bisi et al, 2015, European Journal of Medicinal Chemistry CrossRef
10. Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin
    Taichi Matsumoto et al, 2012, Leukemia & Lymphoma CrossRef
11. The clinical development of antibody–drug conjugates — lessons from leukaemia
    Elias Jabbour et al, 2021, Nature Reviews Clinical Oncology CrossRef
12. Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells
    Takahiro Yamauchi et al, 2012, Cancer Science CrossRef
13. CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
    Francesco Lanza et al, 2020, Cancers CrossRef
14. Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia
    Colin D. Godwin et al, 2020, Leukemia & Lymphoma CrossRef
15. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia
    Akihiro Takeshita, 2013, International Journal of Hematology CrossRef
16. Immunotoxins, Resistance and Cancer Stem Cells: Future Perspective
    Sithambaram Devilakshmi et al, 2015, Resistance to Immunotoxins in Cancer Therapy CrossRef
17. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia
    Mohammed Gbadamosi et al, 2018, Future Oncology CrossRef
18. Discovery and development of ADCs: obstacles and opportunities
    Hsuan Ping Chang et al, 2023, Overcoming Obstacles in Drug Discovery and Development CrossRef